Search
Bayer Forms Exclusive Global License Agreement with Kumquat Biosciences
2025-08-12 /
Read about 0 minute
Author：小编
Bayer has embarked on a collaboration with Kumquat Biosciences, a leading U.S. biotechnology firm, to spearhead the clinical development and commercialization of the KRAS G12D inhibitor innovated by Kumquat. Per the agreement's terms, Kumquat will oversee the completion of the Phase 1a clinical trial, paving the way for Bayer to subsequently drive the drug through to market approval. This groundbreaking medication is designed to target the KRAS G12D gene mutation, a prevalent genetic alteration observed in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
